Title{1}	Randomized, controlled, open label, phase 2 clinical trial of Interferon β-1a (IFNβ-1a) in COVID-19 patients (INTERCOP)
Trial registration {2a and 2b}.	EudraCT 2020-002458-25, registered on May 11, 2020 ClinicalTrials.gov Identifier: NCT04449380
Protocol version {3}	Issue Date: 14 May 2020 Protocol Number: 0
Funding {4}	The sponsor of the trial is IRCCS Ospedale San Raffaele, Milan, Italy. A contract between IRCCS Ospedale San Raffaele (via Olgettina, 60 – Milan, Italy) and Merck Serono S.p.A. (Manufacturer and Marketing Authorization Holder) assigned a grant to cover the costs of drug (Rebif®) supply and delivery.
Author details {5a}	Emanuele Bosi1,2, Carlo Bosi3, Patrizia Rovere Querini1,2, Nicasio Mancini2,4, Giliola Calori5, Annalisa Ruggeri5, Cecilia Canzonieri5, Luciano Callegaro5, Massimo Clementi2,4, Francesco De Cobelli2,6, Massimo Filippi2,7, Marco Bregni5 1Unit of Internal Medicine, IRCCS Ospedale San Raffaele, Milan, Italy; 2Vita-Salute San Raffaele University, Milan, Italy; 3University of Milan Medical School, Milan, Italy; 4Unit of Virology, 5Clinical Trial Center, 6Unit of Radiology and 7Unit of Neurology, IRCCS Ospedale San Raffaele, Milan, Italy
Name and contact information for the trial sponsor {5b}	Trial Sponsor: Prof. Emanuele Bosi – IRCCS Ospedale San Raffaele Address: Via Olgettina, 60 - 20132 Milan – ITALY Email: bosi.emanuele@hsr.it
Role of sponsor {5c}	This is an investigator-initiated trial. IRCCS Ospedale San Raffaele and Merck Serono have no role on the design, collection, management, analysis and interpretation of data. Both entities do not have authority over writing or submitting the report.